Zahid is a board certified pharmaceutical physician with extensive clinical experience in oncology and haematology in a teaching hospital setting and his pharmaceutical experience includes the likes of Cephalon, GlaxoSmithKline and Roche.
His previous role at Roche/Genentech, as Medical Director of Product Development, saw him leading the development of GAZYVA and Rituxan in B-cell malignancies. Zahid is currently an industry consultant, specialising in providing clinical development and medical affairs support to pharmaceutical and biotech companies developing early and late stage oncology and haematology therapeutics. His consulting work has included Bristol-Myers-Squibb, where he was the medical monitor for studies involving immune checkpoint inhibitor, Nivolumab in lung cancer and haematological malignancies. During this time, he was also responsible for the development and implementation of early access to medicine schemes (EAMS) and named-patient programmes (NPP) and post-registration safety studies for patients with malignant melanoma, squamous and non-squamous non-small cell lung cancer, Hodgkin’s lymphoma and multiple myeloma.